Latest Innovation News

Zip Co has delivered a standout half-year performance with record cash earnings and upgraded FY26 guidance, driven by strong US market momentum and innovative product launches.

Aristocrat Leisure reported robust FY25 results with double-digit revenue and profit growth, underpinned by strategic divestments and investments in AI. The company’s FY26 outlook remains positive, driven by market share gains and new product launches.

Beamtree Holdings Limited reported a 2% rise in total revenue and a reduced net loss in the first half of FY26, driven by a 10% increase in recurring revenue. The company is advancing AI-powered healthcare products and has initiated a strategic review to unlock shareholder value.

Ventia Services Group Limited reported a 23.6% increase in profit after tax for FY25 to $272.2 million, alongside record contract wins and a strong sustainability agenda. The company declared a 12.54 cents per share final dividend, underscoring its commitment to shareholder returns and operational excellence.

Australian Vintage reports steady first-half sales and outlines a robust strategy focused on innovation, portfolio diversification, and global expansion to meet full-year growth targets.

Jameson Resources has marked significant progress in advancing its Crown Mountain steelmaking coal project, doubling its pre-tax NPV to US$942 million and moving closer to final environmental approvals and development permits expected by the end of 2026.

Telstra Group Limited reported solid half-year results for December 2025, with revenue and profit growth underpinning a higher dividend and an expanded share buy-back program. The company’s Connected Future 30 strategy continues to drive operational momentum amid disciplined cost management.

MEC Resources Ltd reported a half-year loss of $431,971 amid ongoing legal challenges over key gas exploration permits, while progressing investments in clean energy and neurotechnology. The company also completed a $359K options placement, reinforcing its financial position.

Austco Healthcare has reported a robust first half of 2026, with revenue surging 31% and EBITDA jumping 60%, underpinned by solid contract backlog and debt-free balance sheet.

Nyrada Inc. reported a $3.19 million loss for the half-year ending December 2025, while advancing its lead drug candidate Xolatryp® into Phase IIa clinical trials targeting heart attack treatment.

Knosys Limited reported a 4.6% revenue increase to $5.07 million for the half-year ending December 2025, driven by stronger licence and project fees. However, the company’s net loss widened significantly to $1.53 million, reflecting heavy investment in its next-generation Libero X library management system.

Orthocell has secured a $3 million R&D tax refund, lifting its cash reserves to nearly $50 million and reinforcing its financial strength as it pushes commercialisation of its nerve repair product Remplir™ across key global markets.